Newsroom
Expanded partnership positions XenoSTART and Minerva Imaging at the forefront of radiopharmaceuticals — one of the fastest-growing areas in oncology drug development. The START Center for Cancer Research (“START”), its preclinical division XenoSTART, and Minerva Imaging today announced an expansion of their decade-long partnership to establish the industry’s most comprehensive
START enhances its global leadership by integrating Advarra’s advanced regulatory and technology solutions, creating a seamlessly connected site network to accelerate trials and relieve pressure on the oncology drug development ecosystem The START Center for Cancer Research (“START”), the leading global community-based early-phase oncology research network, today announced a strategic
The START Center for Cancer Research (“START”), the world’s largest early-phase community-based cancer trial site network, today announced the launch of the START Hope Hub, a powerful new digital patient and physician-focused platform that connects patients, caregivers, advocacy groups, and referring oncologists with quick access to START’s 720+ oncology clinical
Partnership Will Launch Three New START Research Sites to Bring Early Phase Trials Closer to Patients in Major U.S. Communities The START Center for Cancer Research (“START”), and OneOncology today announced a strategic partnership to launch early phase clinical trial sites. The rollout includes the Los Angeles Cancer Network (LACN,
Major study milestone highlights START’s commitment to bringing novel cancer therapies to patients through community-based early-phase clinical trials The START Center for Cancer Research (“START”), the world’s largest early-phase community-based oncology site network, today announced the dosing of the first U.S. participant in Moderna’s Phase 1 study evaluating mRNA-4106, a
START’s Site Network Solidifies its Global Leadership in Urological Cancer Trials The START Center for Cancer Research (“START”), a global leader in early-phase oncology clinical trials, announces the expansion of its network with the acquisition of Carolina Urologic Research Center (“CURC”) the premier urologic clinical research site specializing in genitourinary
